COVID 19 is the #80 most commonly reported adverse reaction for PROCHLORPERAZINE, manufactured by Padagis US LLC. There are 264 FDA adverse event reports linking PROCHLORPERAZINE to COVID 19. This represents approximately 0.5% of all 58,040 adverse event reports for this drug.
PROCHLORPERAZINE has an overall safety score of 82 out of 100. Patients taking PROCHLORPERAZINE who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COVID 19264 of 58,040 reports
COVID 19 is a less commonly reported adverse event for PROCHLORPERAZINE, but still significant enough to appear in the safety profile.
Other Side Effects of PROCHLORPERAZINE
In addition to covid 19, the following adverse reactions have been reported for PROCHLORPERAZINE:
COVID 19 has been reported as an adverse event in 264 FDA reports for PROCHLORPERAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COVID 19 with PROCHLORPERAZINE?
COVID 19 accounts for approximately 0.5% of all adverse event reports for PROCHLORPERAZINE, making it a notable side effect.
What should I do if I experience COVID 19 while taking PROCHLORPERAZINE?
If you experience covid 19 while taking PROCHLORPERAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.